1. Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals
- Author
-
José A. Pérez-Molina, Santiago Moreno, Sergio Serrano-Villar, G Caruana, and Alexander Zlotnik
- Subjects
Cyclopropanes ,Male ,0301 basic medicine ,Oncology ,maraviroc ,Human immunodeficiency virus (HIV) ,CD4-CD8 Ratio ,HIV Infections ,medicine.disease_cause ,Maraviroc ,Therapy naive ,chemistry.chemical_compound ,0302 clinical medicine ,T-cell activation ,Pharmacology (medical) ,030212 general & internal medicine ,virus diseases ,efavirenz ,Middle Aged ,Viral Load ,Drug Combinations ,Infectious Diseases ,Lamivudine ,Alkynes ,RNA, Viral ,Female ,Zidovudine ,Adult ,medicine.medical_specialty ,Efavirenz ,Anti-HIV Agents ,antiretroviral therapy ,T cells ,Zidovudine lamivudine ,Antiviral Agents ,Drug Administration Schedule ,03 medical and health sciences ,CD4/CD8 ratio ,Double-Blind Method ,Cyclohexanes ,Internal medicine ,Post-hoc analysis ,medicine ,Humans ,Pharmacology ,business.industry ,HIV ,Triazoles ,Survival Analysis ,Antiretroviral therapy ,Benzoxazines ,030104 developmental biology ,chemistry ,HIV-1 ,business ,Biomarkers - Abstract
A low CD4/CD8 ratio during treated HIV infection reflects heightened immune activation and predicts death. The effects of different antiretroviral therapy regimens on CD4/CD8 ratio recovery remains unclear. We performed a post hoc analysis of the MERIT study, a randomized, double-blind trial of maraviroc versus efavirenz in combination with zidovudine-lamivudine in treatment-naive HIV-infected individuals. We found higher rates of CD4/CD8 ratio normalization with efavirenz, which was driven by a greater CD8 + T-cell decline.
- Published
- 2017